Introduction
As of June 2025, India continues to navigate the evolving landscape of the COVID-19 pandemic, caused by the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). While the country has made significant strides in managing the virus since its first reported case in January 2020, recent surges in cases across Asia have prompted renewed vigilance. This article provides an overview of the current state of COVID-19 in India, including case numbers, dominant variants, vaccination efforts, and public health measures, based on the latest available data.
Current Case Numbers
India has experienced a noticeable uptick in COVID-19 cases in 2025, with active cases rising significantly in May. As of May 31, 2025, the country recorded 2,710 active cases, a sharp increase from 257 on May 19, according to the Ministry of Health and Family Welfare (MoHFW). Kerala leads with 1,147 cases, followed by Maharashtra (424), Delhi (294), Gujarat (223), Karnataka (148), Tamil Nadu (148), and West Bengal (116). In the past week alone, 752 new cases were reported, alongside seven deaths, primarily among individuals with comorbidities. Despite this rise, most cases remain mild, with minimal hospitalizations required.
Dominant Variants
The current wave is driven by the JN.1 variant, a descendant of the Omicron lineage (BA.2.86), which accounts for 53% of sequenced cases in India. JN.1 is highly transmissible due to mutations in its spike protein but is not associated with increased severity. Two new subvariants, NB.1.8.1 and LF.7, classified as Variants Under Monitoring (VUMs) by the World Health Organization (WHO), have also been detected. NB.1.8.1 was first identified in Tamil Nadu in April 2025, while four cases of LF.7 were reported in Gujarat in May. These variants show increased transmissibility and slight immune evasion but cause mild symptoms in most cases.
Symptoms and Health Impact
The symptoms of the JN.1, NB.1.8.1, and LF.7 variants are similar to those of earlier Omicron strains, including fever, cough, sore throat, fatigue, and loss of taste or smell. Some reports indicate JN.1 may present with milder or slightly different symptoms, such as gastrointestinal distress in some cases. While these variants are more transmissible, they are not classified as Variants of Concern (VOCs) by the WHO, and severe illness remains rare, particularly among vaccinated individuals. The seven deaths reported in the last week of May were linked to comorbidities, with Maharashtra reporting two and Delhi, Gujarat, Karnataka, Punjab, and Tamil Nadu reporting one each.
Vaccination and Immunity
India’s vaccination program, launched in January 2021, has been a cornerstone of its COVID-19 response. As of May 2025, over 2.2 billion vaccine doses have been administered, with 95% of eligible adults receiving at least two doses of vaccines like Covishield and Covaxin. However, only 18% of the population has received the 2024–2025 updated booster tailored for Omicron sub-lineages. Production of Covishield and Covaxin ceased in 2021 and 2022, respectively, but government sources confirm an ample stockpile for domestic needs and potential exports. Health experts emphasize that boosters remain effective, reducing symptomatic infection by 50% and severe disease by up to 80%, even against newer variants. Booster uptake, particularly among high-risk groups like the elderly and those with comorbidities, is being encouraged to counter waning immunity.
Public Health Response
The Indian government, through the MoHFW and the Indian SARS-CoV-2 Genomics Consortium (INSACOG), is actively monitoring the situation. Genomic surveillance has been strengthened to track new variants, with samples from affected regions being sequenced regularly. The Integrated Disease Surveillance Programme (IDSP) and ICMR’s respiratory virus sentinel surveillance network are also in place to monitor case trends. Hospitals have been instructed to ensure adequate supplies of beds, oxygen, and medicines, particularly in hotspots like Kerala, Maharashtra, and Delhi. Public health advisories recommend masks in crowded spaces, hand hygiene, and isolation for symptomatic individuals.
Regional and Global Context
The rise in India’s cases mirrors a broader trend across Asia, with Singapore reporting 14,200 cases and Hong Kong noting a test positivity rate of 13.66% in early May. The WHO attributes these spikes to waning population immunity and the emergence of new variants like NB.1.8.1, which accounts for 10.7% of global sequences. India’s health authorities are closely monitoring these trends, especially given global travel’s role in viral spread. Unlike earlier waves, India’s healthcare system is better prepared, with no significant strain reported despite the uptick.
Challenges and Concerns
Despite the low severity, challenges remain. Vaccine hesitancy, driven by misinformation and logistical issues, hinders booster uptake. The unpredictable seasonal pattern of respiratory illnesses and diminishing immunity from prior infections or vaccinations could fuel further spikes. Experts warn that while current variants are mild, a rapid increase in cases could pressure healthcare systems, particularly in densely populated urban areas like Delhi, Mumbai, and Bengaluru.
Recommendations for the Public
Health officials recommend the following to curb the spread of COVID-19:
- Get Boosted: High-risk groups, including the elderly and those with comorbidities, should prioritize booster shots.
- Wear Masks: Use masks in crowded or enclosed spaces, especially in hotspot areas.
- Practice Hygiene: Regular handwashing and avoiding contact with sick individuals remain crucial.
- Test Early: Mild symptoms like sore throat or fatigue warrant prompt testing, ideally with RT-PCR for confirmation.
- Stay Informed: Follow updates from the MoHFW and local health authorities for region-specific guidelines.
Conclusion
India’s COVID-19 situation in 2025 reflects a manageable but evolving challenge. With 2,710 active cases as of May 31, driven primarily by the JN.1 variant and emerging subvariants NB.1.8.1 and LF.7, the country is not in crisis but cannot afford complacency. Robust vaccination coverage, genomic surveillance, and public health measures provide a strong foundation for response. By prioritizing boosters, maintaining vigilance, and adhering to preventive measures, India can mitigate the impact of this resurgence and continue its progress toward long-term management of COVID-19 as an endemic disease.
